Matthew Feshbach is CEO and co-founder of Okyanos Heart Institute, which brings a new option, standard of care and quality of life to patients with coronary artery disease (CAD), utilizing cell therapy technology from the growing field of stem cell therapeutics. Based in Freeport, The Bahamas, Okyanos Heart Institute is a center of excellence adhering to U.S. surgical center standards.
Prior to the creation of Okyanos Heart Institute, Matt’s career spanned more than 30 years as an investor. In 2009 he and his brother, Joe, began researching adult stem cells and their potential due to their interest in a public company to which they had been introduced by a financial partner. Extensive research led Matt to believe that stem cell therapy could provide an answer to the largest unmet healthcare need in the Western world: heart attack and heart disease. Read Matthew Feshbach’s full bio »
Manuel Vianna serves as the Chief Operating Officer of Okyanos. He has a rich, diverse and global business background. As a partner and board member of Monitor Group, a global investment and consulting firm in Cambridge, Massachussets, he guided important client companies and countries in developing and implementing successful innovation, growth and turnarounds strategies.
Manuel’s extensive experience and capabilities span the spectrum of strategy, operations, finance, value creation and investment. Read Manuel Vianna’s full bio »
Howard Walpole, MD, serves as the interventional cardiologist and chief medical officer at Okyanos Heart Institute in Freeport, Bahamas. The mission of this medical facility is to provide stem cell therapy to patients with no-option coronary artery disease (CAD).
Dr. Walpole is a prominent U.S.-educated interventional cardiologist. Dr. Walpole, in his 25 years of practice, has done approximately 5,000 catheter-based interventions and 12,000 diagnostic catheterizations, as well as myocardial (heart) biopsies. Read Howard Walpole’s full bio »
Scott Vickers is the Patient Liaison Director at Okyanos. Serving as the first point of contact for many of our patients, he is responsible for educating patients about cardiac cell therapy as a treatment option for patients with advanced coronary artery disease. In order to provide a high level of personalized care, he may also act as a liaison between our Chief Medical Officer and your cardiologist in the process of learning about Okyanos Treatment and whether you are a candidate for our procedure. Read Scott Vickers’ full bio »